ATA3219: Developing Off-the-Shelf Allogeneic CD19 Program for B-Cell Malignancies, With IND Expected in Q2 2023
Academic program generated proof of principle for EBV T-cell platform potential to generate off-the-shelf, allogeneic CAR T immunotherapies ATA3219: Next-generation off-the-shelf, allogeneic CD19-1XX CAR+ EBV T-cell immunotherapy containing a modified CD3ζ signaling domain, 1XX.
Allogeneic CAR T targeting CD19, currently in preclinical development, leverages our EBV T-cell platform and features a next-generation 1XX co-stimulatory domain.LEARN MORE
- Phase 1
- Phase 2
- Phase 3
- Target: CD19
- Technologies: Novel CAR T 1XX co-stimulation
- Off-the-shelf, allogeneic
Next-Generation CAR T Technology
Our preclinical pipeline is rapidly expanding with novel technologies and next-generation, multi-targeted CAR T immunotherapies thanks to our collaborations with Moffitt Cancer Center and Memorial Sloan Kettering Cancer Center.